Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Frits Van Rhee

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Myeloma
Address8-186 Cancer Institute
4104 Outpatient Circle
Mail Slot # 816
Little Rock AR 72205
Phone501-526-2873
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute


    Collapse Research Funds 
    Collapse principal investigator/co-principal investigator research activities
    R01 HL 141408     (VAN RHEE, FRITS)Jun 15, 2018 - May 31, 2023
    NIH/Nat. Cancer Institute - Pass Through: University of Pennsylvania
    mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target
    Role: Principal Investigator

    R01HL141408     (VAN RHEE, FRITS)Jun 15, 2018 - May 31, 2023
    NIH/Nat. Cancer Institute - Pass Through: University of Pennsylvania
    mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target
    Role: Principal Investigator

    M13-367     (VAN RHEE, FRITS)Apr 26, 2018 - May 15, 2019
    AbbVie Inc
    A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
    Role: Principal Investigator

    GSK525762     (VAN RHEE, FRITS)Aug 9, 2017
    GlaxoSmithKline
    A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with
    Role: Principal Investigator

    54767414MMY2023     (VAN RHEE, FRITS)Jun 15, 2017
    Janssen Research & Development, LLC
    Janssen 54767414MMY2023
    Role: Principal Investigator

    M15-538     (VAN RHEE, FRITS)May 30, 2017
    AbbVie Inc
    A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomiib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Role: Principal Investigator

    CA204-151     (VAN RHEE, FRITS)Mar 16, 2017 - Mar 16, 2020
    Bristol-Meyers Squibb
    A Phase II Pilot Study of Expanded Natural Killer Cells and Elotuzumab to Eradicate High-Risk Myeloma Post Autologous Stem Cell Transplant
    Role: Principal Investigator

    INSIGHT MM     (VAN RHEE, FRITS)Jun 6, 2016 - Jun 29, 2017
    Millennium Pharmaceuticals, Inc.
    the INSIGHT-MM study
    Role: Principal Investigator

    Edmonston Strain of Measles Virus     (VAN RHEE, FRITS)Apr 8, 2015
    Magnis Therapeutics, LLC
    UARK 2014-21: Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS with Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma
    Role: Principal Investigator

    UARK# 2012-02     (VAN RHEE, FRITS)Apr 21, 2014
    Onyx Pharmaceuticals, Inc.
    UARK# 2012-02 TOTAL THERAPY 5B: A PHASE II TRIAL FOR HIGH-RISK MYELOMA EVALUATING ACCELERATING AND SUSTAINING COMPLETE REMISSION (AS-CR) BY APPLYING N
    Role: Principal Investigator

    JNJ28431754     (VAN RHEE, FRITS)Apr 14, 2011 - Feb 16, 2016
    Centocor, Inc.
    Protocol CNTO328MCD2002; Phase 2, An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Mult
    Role: Principal Investigator

    CNTO 328     (VAN RHEE, FRITS)Dec 30, 2009 - May 9, 2013
    Centocor, Inc.
    A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv
    Role: Principal Investigator

    Zoster-001 PRI     (VAN RHEE, FRITS)Dec 23, 2009
    GlaxoSmithKline
    A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to evaluate the Safety and Immunogenicity of the GSK Biologicals’ Herp
    Role: Principal Investigator

    KOS953     (VAN RHEE, FRITS)Jul 1, 2009
    Bristol-Meyers Squibb
    Phase 3 Randomized, open-label clinical trial of tanespimycin (KO953) plus Bortezomib Compared to bortezomib alone in patients with multiple myeloma i
    Role: Principal Investigator

    BCT07-30     (VAN RHEE, FRITS)Feb 24, 2009 - Aug 24, 2010
    CaridianBCT
    Engraftment Kinetics of Peripheral Blood Stem Cells (PBSC's) Isolated Using the Spectra Optia Apheresis System
    Role: Principal Investigator

    CRA UARK 2006-41, Prot. HuLuc63-1701     (VAN RHEE, FRITS)Sep 1, 2008 - Mar 30, 2010
    Protein Design Labs, Inc
    UARK 2006-41 A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal lgG1 antibody) in Subjects with Adva
    Role: Principal Investigator

    KAG     (VAN RHEE, FRITS)Aug 27, 2008 - Aug 26, 2010
    Genzyme
    KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple
    Role: Principal Investigator

    R01CA134522     (VAN RHEE, FRITS)Aug 22, 2008 - Jun 30, 2014
    NIH/NCI
    Potentiating Natural Killer Cell Anti-Myeloma Effects
    Role: Principal Investigator

    A2-7438     (VAN RHEE, FRITS)Jul 25, 2008 - Jul 24, 2013
    United BioSource Corporation
    Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438
    Role: Principal Investigator

    28-06     (VAN RHEE, FRITS)Oct 1, 2006 - Sep 30, 2008
    Multiple Myeloma Research Foundation
    KIRLigand Mismatched Natural Killer Cell Therapy for Myeloma
    Role: Principal Investigator

    AMD3100-3102 CTA     (VAN RHEE, FRITS)May 6, 2005 - Apr 30, 2008
    AnorMED, Inc.
    UARK 2004-61: (AMD3100-3102) A Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 ug/kg) plus G-CSF (10 ug/k
    Role: Principal Investigator

    C0328T03 28552 CTA     (VAN RHEE, FRITS)Mar 4, 2005 - Aug 31, 2007
    Centocor, Inc.
    2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion
    Role: Principal Investigator

    2003-41 Amgen 20020791 CTAA1     (VAN RHEE, FRITS)Aug 27, 2004 - Jun 1, 2006
    Amgen, Inc.
    UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma
    Role: Principal Investigator

    AMD3100-2105 CTA     (VAN RHEE, FRITS)Jun 3, 2004 - Jan 31, 2008
    AnorMED, Inc.
    2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv
    Role: Principal Investigator

    AMD3100-2102 Amend1     (VAN RHEE, FRITS)Apr 17, 2003 - Apr 17, 2006
    AnorMED, Inc.
    UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma
    Role: Principal Investigator

    UARK 2002-13     (VAN RHEE, FRITS)Feb 1, 2003 - Jan 31, 2006
    Celgene Corporation
    UARK 2003-26, A Pilot Study of MAGE-3 and NY_ESO Immunotherapy in Combination with DT PACE Chemotherapy/Autologous Transplant in Agressive Mutliple My
    Role: Principal Investigator

    UARK 2002-36     (VAN RHEE, FRITS)Dec 1, 2002 - Nov 30, 2005
    Chugai Biopharmaceuticals, Inc.
    UARK 2002-36, An Open Label, Phase I Extension Study to Assess the Long-Term Safety and Tolerability of MRA as a Treatment for Castleman’s Disease
    Role: Principal Investigator

    6653-01     (VAN RHEE, FRITS)Jul 1, 2001 - Dec 30, 2004
    Leukemia & Lymphoma Society
    Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Fajgenbaum DC, Langan RA, Sada Japp A, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 Aug 13; 130. PMID: 31408438.
      View in: PubMed
    2. Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer J. 2019 Aug 09; 9(8):62. PMID: 31399558.
      View in: PubMed
    3. Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis? Theranostics. 2019; 9(16):4756-4763. PMID: 31367255.
      View in: PubMed
    4. Nabel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdivieso F, Feldman MD, Chadburn A, Fosså A, van Rhee F, Lipkin WI, Fajgenbaum DC. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One. 2019; 14(6):e0218660. PMID: 31242229.
      View in: PubMed
    5. Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clin Proc. 2019 Sep; 94(9):1834-1839. PMID: 31235278.
      View in: PubMed
    6. van Rhee F, Stone K. Storming the Castle with TCP. Blood. 2019 Apr 18; 133(16):1697-1698. PMID: 31000513.
      View in: PubMed
    7. Ashby C, Tytarenko RG, Wang Y, Weinhold N, Johnson SK, Bauer M, Wardell CP, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Davies FE, Sawyer JR, Morgan GJ, Walker BA. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 Jan 22; 10(7):732-737. PMID: 30774775.
      View in: PubMed
    8. Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2019 Feb; 184(4):578-593. PMID: 30408155.
      View in: PubMed
    9. Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol. 2019 01; 184(2):232-241. PMID: 30203839.
      View in: PubMed
    10. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. PMID: 30181172.
      View in: PubMed
    11. Qiang YW, Ye S, Huang Y, Chen Y, Van Rhee F, Epstein J, Walker BA, Morgan GJ, Davies FE. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer. 2018 Jul 06; 18(1):724. PMID: 29980194.
      View in: PubMed
    12. Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M, Van Rhee F, Rico JC. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol. 2019 Apr; 185(1):187-189. PMID: 29974956.
      View in: PubMed
    13. Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 07 05; 132(1):59-66. PMID: 29784643.
      View in: PubMed
    14. Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol. 2018 07; 93(7):902-912. PMID: 29675946.
      View in: PubMed
    15. Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. Mayo Clin Proc. 2018 04; 93(4):542-544. PMID: 29622102.
      View in: PubMed
    16. Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 11; 32(11):2435-2444. PMID: 29654269.
      View in: PubMed
    17. Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 06; 103(6):1047-1053. PMID: 29567784.
      View in: PubMed
    18. Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res. 2018 06 15; 24(12):2913-2919. PMID: 29563136.
      View in: PubMed
    19. Gralewski JH, Post GR, van Rhee F, Yuan Y. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Diagn Pathol. 2018 Feb 20; 13(1):15. PMID: 29463311.
      View in: PubMed
    20. van Rhee F, Greenway A, Stone K. Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am. 2018 02; 32(1):89-106. PMID: 29157622.
      View in: PubMed
    21. van Rhee F, Munshi NC. Castleman Disease. Hematol Oncol Clin North Am. 2018 02; 32(1):xiii-xiv. PMID: 29157623.
      View in: PubMed
    22. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017 Aug; 92(8):739-745. PMID: 28383130.
      View in: PubMed
    23. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367. PMID: 28550191.
      View in: PubMed
    24. Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 08; 102(8):e313-e316. PMID: 28522572.
      View in: PubMed
    25. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 07 06; 130(1):30-34. PMID: 28432222.
      View in: PubMed
    26. Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017 Apr; 55:190-199. PMID: 28431262.
      View in: PubMed
    27. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res. 2017 Jun; 32(6):1261-1266. PMID: 28240368.
      View in: PubMed
    28. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Mar 23; 129(12):1646-1657. PMID: 28087540.
      View in: PubMed
    29. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601.
      View in: PubMed
    30. Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res. 2017 Jun 01; 23(11):2665-2672. PMID: 27810902.
      View in: PubMed
    31. Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016 12 22; 128(25):2919-2930. PMID: 27793878.
      View in: PubMed
    32. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res. 2017 04 15; 23(8):1981-1987. PMID: 27698001.
      View in: PubMed
    33. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 09 29; 128(13):1735-44. PMID: 27516441.
      View in: PubMed
    34. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016 Apr; 3(4):e163-75. PMID: 27063975.
      View in: PubMed
    35. Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84. PMID: 26888183.
      View in: PubMed
    36. Jethava YS, van Rhee F. Transplantation for Multiple Myeloma. Cancer Treat Res. 2016; 169:227-250. PMID: 27696266.
      View in: PubMed
    37. Mathur P, Paydak H, Thanendrarajan S, van Rhee F. Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):70-5. PMID: 26776085.
      View in: PubMed
    38. van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015 Oct 06; 6(30):30408-19. PMID: 26327301.
      View in: PubMed
    39. Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015 Oct 01; 21(19):4294-304. PMID: 26124203.
      View in: PubMed
    40. Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015 Sep; 100(9):1214-21. PMID: 26022710.
      View in: PubMed
    41. Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 2015 Jun 11; 125(24):3756-9. PMID: 25943786.
      View in: PubMed
    42. van Rhee F, Rothman M, Ho KF, Fleming S, Wong RS, Fosså A, Dispenzieri A, Cavet J, Munshi N, Vermeulen J, Casper C. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient. 2015 Apr; 8(2):207-16. PMID: 25736164.
      View in: PubMed
    43. Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B. Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. Clin Case Rep. 2015 Mar; 3(3):183-92. PMID: 25838910.
      View in: PubMed
    44. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285.
      View in: PubMed
    45. Morgan GJ, van Rhee F. Haematological cancer: Optimizing the treatment of multiple myeloma. Nat Rev Clin Oncol. 2014 Dec; 11(12):686-8. PMID: 25348792.
      View in: PubMed
    46. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014 Nov 13; 124(20):3043-51. PMID: 25293776.
      View in: PubMed
    47. Liu YC, Stone K, van Rhee F. Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014 Oct; 7(5):545-57. PMID: 25110138.
      View in: PubMed
    48. Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S. CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood. 2014 Sep 25; 124(13):2051-60. PMID: 25061178.
      View in: PubMed
    49. van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug; 15(9):966-74. PMID: 25042199.
      View in: PubMed
    50. van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014 Jul 17; 124(3):328-33. PMID: 24894774.
      View in: PubMed
    51. Liu YC, Szmania S, van Rhee F. Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood Lymphat Cancer. 2014 Jun; 2014(4):15-27. PMID: 26005365.
      View in: PubMed
    52. van Rhee F. Engineering more efficacious antibody therapy for myeloma. Blood. 2014 May 15; 123(20):3062-3. PMID: 24832938.
      View in: PubMed
    53. Tian E, Sawyer JR, Heuck CJ, Zhang Q, van Rhee F, Barlogie B, Epstein J. In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes. Genes Chromosomes Cancer. 2014 Jul; 53(7):549-57. PMID: 24638926.
      View in: PubMed
    54. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014 May 08; 123(19):2924-33. PMID: 24622327.
      View in: PubMed
    55. Liu YC, Reddi HV, Waheed S, Alapat D, Highsmith WE, Edmondson RD, Barlogie B, van Rhee F. A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis. Amyloid. 2014 Jun; 21(2):134-5. PMID: 24517438.
      View in: PubMed
    56. Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014 Apr 17; 123(16):2504-12. PMID: 24497533.
      View in: PubMed
    57. Batchu RB, Gruzdyn OV, Moreno-Bost AM, Szmania S, Jayandharan G, Srivastava A, Kolli BK, Weaver DW, van Rhee F, Gruber SA. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine. 2014 Feb 12; 32(8):938-43. PMID: 24406390.
      View in: PubMed
    58. Lapteva N, Szmania SM, van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014; 19(1-2):121-32. PMID: 24941378.
      View in: PubMed
    59. Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D, Barlogie B, Usmani SZ. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):211-4. PMID: 24373936.
      View in: PubMed
    60. Reddi HV, Jenkins S, Theis J, Thomas BC, Connors LH, Van Rhee F, Highsmith WE. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life. J Mol Diagn. 2014 Jan; 16(1):68-74. PMID: 24184229.
      View in: PubMed
    61. Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang YW. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013; 8(9):e74191. PMID: 24066119.
      View in: PubMed
    62. Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D, Keller J, Waheed S, Usmani SZ, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica. 2013 Jul; 98(7):1147-53. PMID: 23716540.
      View in: PubMed
    63. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 01; 19(13):3659-70. PMID: 23659971.
      View in: PubMed
    64. Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun 06; 121(23):4753-7. PMID: 23603914.
      View in: PubMed
    65. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol. 2013 Jun; 88(6):463-71. PMID: 23456977.
      View in: PubMed
    66. Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013 Jun; 41(6):547-557.e2. PMID: 23435312.
      View in: PubMed
    67. Fajgenbaum DC, Fajgenbaum D, Rosenbach M, van Rhee F, Nasir A, Reutter J. Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. JAMA Dermatol. 2013 Feb; 149(2):204-8. PMID: 23426475.
      View in: PubMed
    68. Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One. 2013; 8(1):e54610. PMID: 23372742.
      View in: PubMed
    69. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013 Mar 07; 121(10):1819-23. PMID: 23305732.
      View in: PubMed
    70. Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B. Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. Clin Cancer Res. 2012 Oct 01; 18(19):5499-506. PMID: 22855579.
      View in: PubMed
    71. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2013 Jan; 98(1):71-8. PMID: 22733020.
      View in: PubMed
    72. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012 Nov; 97(11):1761-7. PMID: 22689675.
      View in: PubMed
    73. Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012 Aug 23; 120(8):1597-600. PMID: 22674807.
      View in: PubMed
    74. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012 Sep; 97(9):1348-56. PMID: 22419581.
      View in: PubMed
    75. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012 Jul 19; 120(3):552-9. PMID: 22184404.
      View in: PubMed
    76. Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011 Sep 29; 118(13):3512-24. PMID: 21628408.
      View in: PubMed
    77. Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD, van Rhee F, Nair B, Barlogie B, Epstein J, Yaccoby S. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011 Feb; 29(2):263-73. PMID: 21732484.
      View in: PubMed
    78. Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, Shaughnessy J, Barlogie B, Prentice HG, van Rhee F. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 2011 May; 13(5):618-28. PMID: 21171821.
      View in: PubMed
    79. Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer. 2011 Mar 01; 117(5):1001-9. PMID: 20945320.
      View in: PubMed
    80. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug 10; 28(23):3701-8. PMID: 20625121.
      View in: PubMed
    81. Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010 Sep; 150(5):554-64. PMID: 20618329.
      View in: PubMed
    82. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010 Jul; 8(7):486-98. PMID: 20864917.
      View in: PubMed
    83. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J, Barlogie B. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010 Aug 26; 116(8):1220-7. PMID: 20501894.
      View in: PubMed
    84. Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD, Szymonifka J, Hoering A, Petty N, Crowley J. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol. 2010 Jun 20; 28(18):3023-7. PMID: 20479421.
      View in: PubMed
    85. van Rhee F. Light-chain MGUS: implications for clinical practice. Lancet. 2010 May 15; 375(9727):1670-1. PMID: 20472153.
      View in: PubMed
    86. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A. 2010 Apr 27; 107(17):7904-9. PMID: 20385818.
      View in: PubMed
    87. Nair B, van Rhee F, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010 May 27; 115(21):4168-73. PMID: 20124509.
      View in: PubMed
    88. Nair B, Van RF, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood. 2010.
    89. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 01; 28(7):1209-14. PMID: 20085933.
      View in: PubMed
    90. Van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. CNTO 328, a Novel- Anti-Interleukin-6 Monoclonal Antibody, is an Active Treatment for Castleman Disease. J Clin Oncol. 2010.
    91. Van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy Jr JD, Hoering A, Crowley J, Barlogie B. Total Therapy 3 (2003-33) in Gene Expression Profiling-Defined Low-Risk Multiple Myeloma Confirmed in Subsequent Trial 2006-66 with Bortezemib, Lenalidomide and Dexamethasone (VRD) Maintenance. Blood. 2010.
    92. Van Rhee F, Anaissie E, Angtuaco E, Bartel T, Epstein J, Nair B, Shaughnessy Jr J, Yaccoby S, Barlogie B. Williams Hematology. Myeloma. 2010; 9.
    93. van Rhee F. Turning up the heat on myeloma. Blood. 2009 Oct 29; 114(18):3724-5. PMID: 19875523.
      View in: PubMed
    94. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep; 8(9):2616-24. PMID: 19723891.
      View in: PubMed
    95. Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J, Barlogie B. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol. 2009 Nov; 147(3):347-51. PMID: 19702643.
      View in: PubMed
    96. Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood. 2009 Aug 13; 114(7):1299-305. PMID: 19515721.
      View in: PubMed
    97. Bartel TB, Haessler J, Brown TL, Shaughnessy JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009 Sep 03; 114(10):2068-76. PMID: 19443657.
      View in: PubMed
    98. Nair B, Shaughnessy JD, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood. 2009 Jun 25; 113(26):6572-5. PMID: 19389881.
      View in: PubMed
    99. Zhou Y, Nair B, Shaughnessy JD, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol. 2009 Jun; 145(5):637-41. PMID: 19344415.
      View in: PubMed
    100. Van rhee F, Nair, B. Hematopoietic Stem Cell Transplantation. Multiple Myeloma. 2009; 8.
    101. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec; 143(5):641-53. PMID: 18950462.
      View in: PubMed
    102. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica. 2008 Nov; 93(11):1739-42. PMID: 18728024.
      View in: PubMed
    103. Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008 Oct 15; 112(8):3122-5. PMID: 18669874.
      View in: PubMed
    104. Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B, Crowley J. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. Cancer. 2008 Jun 15; 112(12):2720-5. PMID: 18433012.
      View in: PubMed
    105. van Rhee F, Dhodapkar M, Shaughnessy JD, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade. Blood. 2008 Aug 15; 112(4):1035-8. PMID: 18502827.
      View in: PubMed
    106. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008 Oct 15; 112(8):3115-21. PMID: 18492953.
      View in: PubMed
    107. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 01; 14(9):2775-84. PMID: 18451245.
      View in: PubMed
    108. Van RF, Shaughnessy Jr JD, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade later. Blood. 2008.
    109. Pineda-Roman, M, Barlogie, B, Anaissie, E, Zangari, M, Bolejack, V, Van Rhee, F, Tricot, G, Crowley, J. High-dose melphalan-based autotransplants for muliple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008; 112(8):1754-1764.
    110. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008 Apr 15; 112(8):1754-64. PMID: 18300230.
      View in: PubMed
    111. Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol. 2008 May; 141(4):433-44. PMID: 18371114.
      View in: PubMed
    112. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD, Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008 Mar; 140(6):625-34. PMID: 18302711.
      View in: PubMed
    113. Van RF, Crowley J, Barlogie B. Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness. Blood. 2008; 111(4):2491 - .
    114. Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007 Dec 01; 13(23):7073-9. PMID: 18056185.
      View in: PubMed
    115. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):761-81. PMID: 18070718.
      View in: PubMed
    116. van Rhee F. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients? Nat Clin Pract Oncol. 2008 Feb; 5(2):70-1. PMID: 17984985.
      View in: PubMed
    117. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007 Nov-Dec; 30(8):847-54. PMID: 18049337.
      View in: PubMed
    118. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B, van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008 Feb 01; 111(3):1309-17. PMID: 17947507.
      View in: PubMed
    119. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008 Jan 01; 111(1):94-100. PMID: 17895401.
      View in: PubMed
    120. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007 Jul; 138(2):176-85. PMID: 17593024.
      View in: PubMed
    121. van Rhee F, Crowley J, Barlogie B. Allografting or autografting for myeloma. N Engl J Med. 2007 Jun 21; 356(25):2646-8; author reply 2646-8. PMID: 17582078.
      View in: PubMed
    122. Shaughnessy JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007 Jun; 137(6):530-6. PMID: 17489983.
      View in: PubMed
    123. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 01; 110(3):827-32. PMID: 17416735.
      View in: PubMed
    124. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar 20; 25(9):1121-8. PMID: 17296972.
      View in: PubMed
    125. Moreno A, Van rhee F. Cancer and Gene Therapy. Retroviral applications for the immunotherapy of cancer. 2007; 13.
    126. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, Walker R, Hollmig K, Shaughnessy JD, Epstein J, Krishna S, Crowley J, Barlogie B. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol. 2007 Feb; 136(3):393-9. PMID: 17156398.
      View in: PubMed
    127. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84. PMID: 17105813.
      View in: PubMed
    128. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15; 109(4):1692-700. PMID: 17023574.
      View in: PubMed
    129. Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma. 2006 Oct; 47(10):2037-48. PMID: 17071474.
      View in: PubMed
    130. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64. PMID: 16939489.
      View in: PubMed
    131. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood. 2006 Sep 15; 108(6):2020-8. PMID: 16728703.
      View in: PubMed
    132. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006 Sep 01; 108(5):1724-32. PMID: 16705089.
      View in: PubMed
    133. van Rhee F. Con: allogeneic transplantation in multiple myeloma. Clin Adv Hematol Oncol. 2006 May; 4(5):391-4. PMID: 16728948.
      View in: PubMed
    134. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma. 2006 May; 6(6):469-74. PMID: 16796777.
      View in: PubMed
    135. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30. PMID: 16525139.
      View in: PubMed
    136. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006 Apr 01; 107(7):2633-8. PMID: 16322468.
      View in: PubMed
    137. Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res. 2005 Nov 01; 65(21):10041-9. PMID: 16267030.
      View in: PubMed
    138. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005 May 15; 105(10):3939-44. PMID: 15671442.
      View in: PubMed
    139. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep; 126(5):715-21. PMID: 15327525.
      View in: PubMed
    140. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol. 2004 Apr; 125(1):24-30. PMID: 15015964.
      View in: PubMed
    141. Safdar A, Bruorton M, Henslee-Downey JP, Van RF. Role of quantitative human cytomegalovirus PCR in predicting antiviral treatment response among high-risk hematopoietic stem-cell transplant recipients. Bone Marrow Transplant. 2004; 33(4):463 - 464.
    142. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9. PMID: 12860952.
      View in: PubMed
    143. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5. PMID: 12837152.
      View in: PubMed
    144. Fassas AB, Van Rhee F, Tricot G. Predicting long-term survival in multiple myeloma patients following autotransplants. Leuk Lymphoma. 2003 May; 44(5):749-58. PMID: 12802910.
      View in: PubMed
    145. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80. PMID: 12543109.
      View in: PubMed
    146. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002 Mar 01; 99(5):1745-57. PMID: 11861292.
      View in: PubMed
    147. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002 Mar 01; 20(5):1295-303. PMID: 11870172.
      View in: PubMed
    148. Van RF. Identification and isolation of Ag-specific T cells by flow sorting. Cytotherapy. 2002; 4(1):93 - 95.
    149. Dodi IA, Van RF, Forde HC, Roura-Mir C, Jaraquemada D, Goldman JM, Madrigal JA. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy. 2002; 4(4):353 - 363.
    150. Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, Van RF, Kaeda J, Cross NC, Craddock C, Kanfer E, Apperley J, Goldman JM. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol. 2001; 115(3):569 - 574.
    151. Chiang KY, Hazlett LJ, Godder KT, Abhyankar SH, Christiansen NP, Van RF, Lee CG, Bridges K, Parrish RS, Henslee-Downey PJ. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 2001; 28(12):1117 - 1123.
    152. Szmania S, Galloway A, Bruorton M, Musk P, Aubert G, Arthur A, Pyle H, Hensel N, Ta N, Lamb L, Dodi T, Madrigal A, Barrett J, Henslee-Downey J, Van RF. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 2001; 98(3):505 - 512.
    153. Musk P, Szmania S, Galloway AT, Johnson K, Scott A, Guttman S, Bridges K, Bruorton M, Gatlin J, Garcia JV, Lamb L, Chiang KY, Spencer T, Henslee-Downey J, Van RF. In vitro generation of Epstein-Barr virus-specific cytotoxic T cells in patients receiving haplo-identical allogeneic stem cell transplantation. J Immunother (1997 ). 2001; 24(4):312 - 322.
    154. Lamb LS, Musk P, Ye Z, Van RF, Geier SS, Tong JJ, King KM, Henslee-Downey PJ. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 2001; 27(6):601 - 606.
    155. Craddock C, Szydlo RM, Klein JP, Dazzi F, Olavarria E, Van RF, Pocock C, Cwynarski K, Apperley JF, Goldman JM. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000; 96(1):86 - 90.
    156. Sloand EM, Kim S, Maciejewski JP, Van RF, Chaudhuri A, Barrett J, Young NS. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000; 95(7):2269 - 2274.
    157. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, Olavarria E, Van RF, Kanfer E, Apperley JF, Goldman JM. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000; 95(1):67 - 71.
    158. Van rhee F, Kolb HJ. Allogeneic Immunotherapy for Malignant Transfusion. The GVL Effect in Donor Lymphocyte Transfusion. 2000.
    159. Van RF, Jiang YZ, Vigue F, Kirby M, Mavroudis D, Hensel NF, Agarwala V, Clave E, Childs R, Raptis A, Sloand E, Carter C, Read EJ, Barrett J. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. Br J Haematol. 1999; 105(4):1014 - 1024.
    160. Henslee-Downey PJ, Godder K, Abhyankar S, Chiang KY, Lamb LS, Geier SS, Van rhee F, Singhal S, Mehta J. Hematology. Sequential immunomodualtions to achieve engraftment and contro graft-versus-host disease across mismatched MHC barriers. 1999.
    161. Childs R, Sanchez C, Engler H, Preuss J, Rosenfeld S, Dunbar C, Van RF, Plante M, Phang S, Barrett AJ. High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant. 1998; 22(9):889 - 893.
    162. Raptis A, Clave E, Mavroudis D, Molldrem J, Van RF, Barrett AJ. Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells?. Br J Haematol. 1998; 102(5):1354 - 1358.
    163. Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, Van RF, Hensel N, Fellowes V, Eliopoulos G, Barrett AJ. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol. 1998; 101(3):565 - 570.
    164. Van Rhee MA, Holm JP, Niermeijer MF. [Genetic carrier screening for hemoglobinopathies: the situation in the Netherlands compared with England]. Ned Tijdschr Geneeskd. 1998; 142(18):996 - 997.
    165. Van RF, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F, Chase A, Bungey J, Cross NC, Apperley J, Szydlo R, Goldman JM. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998; 21(10):1055 - 1061.
    166. Raanani P, Dazzi F, Sohal J, Szydlo RM, Van RF, Reiter A, Lin F, Goldman JM, Cross NC. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997; 99(4):945 - 950.
    167. Van RF, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, De WT, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997; 20(7):553 - 560.
    168. Barrett AJ, Van RF. Graft-versus-leukaemia. Baillieres Clin Haematol. 1997; 10(2):337 - 355.
    169. Aguiar RC, Sohal J, Van RF, Carapeti M, Franklin IM, Goldstone AH, Goldman JM, Cross NC. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol. 1996; 95(4):673 - 677.
    170. Van RF, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996; 87(12):5213 - 5217.
    171. Lin F, Van RF, Goldman JM, Cross NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood. 1996; 87(10):4473 - 4478.
    172. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, Van RF, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood. 1996; 87(4):1549 - 1555.
    173. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, Van RF, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood. 1995; 86(9):3590 - 3597.
    174. Van RF, Kolb HJ. Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol. 1995; 2(6):423 - 430.
    175. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Van RF, Mittermueller J, De WT, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995; 86(5):2041 - 2050.
    176. Hochhaus A, Lin F, Reiter A, Skladny H, Van RF, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol. 1995; 91(1):126 - 131.
    177. Jadayel D, Calabrese G, Min T, Van RF, Swansbury GJ, Dyer MJ, Maitland J, Palka G, Catovsky D. Molecular cytogenetics of chronic myeloid leukemia with atypical t(6;9) (p23;q34) translocation. Leukemia. 1995; 9(6):981 - 987.
    178. Spencer A, Brookes PA, Kaminski E, Hows JM, Szydlo RM, Van RF, Goldman JM, Batchelor JR. Cytotoxic T lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors. Value in donor selection. Transplantation. 1995; 59(9):1302 - 1308.
    179. Van RF, Kasprzyk A, Jamil A, Dickinson H, Lin F, Cross NC, Galvin MC, Goldman JM, Secker-Walker LM. Detection of the BCR-ABL gene by reverse transcription/polymerase chain reaction and fluorescence in situ hybridization in a patient with Philadelphia chromosome negative acute lymphoblastic leukaemia. Br J Haematol. 1995; 90(1):225 - 228.
    180. Van RF, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NC, Goldman JM. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia. 1995; 9(2):329 - 335.
    181. Van RF, Lin F, Cross NC, Reid CD, Lakhani AK, Szydlo RM, Goldman JM. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 1994; 14(4):609 - 612.
    182. Datta AR, Barrett AJ, Jiang YZ, Guimaraes A, Mavroudis DA, Van RF, Gordon AA, Madrigal A. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant. 1994; 14(4):517 - 524.
    183. Garicochea B, Van RF, Spencer A, Chase A, Lin F, Cross NC, Goldman JM. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). Br J Haematol. 1994; 88(2):400 - 402.
    184. Van RF, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994; 83(11):3377 - 3383.
    185. Ward KN, Roberts IA, Van RF. Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital. Bone Marrow Transplant. 1994; 13(2):230 - 231.
    186. Van RF, Ware I, Littlewood T. Abnormal haemoglobin electrophoresis caused by BW 12C. J Clin Pathol. 1992; 45(10):930 - .
    187. Van RF, Balsitis M, French EA. Fatal splenic sequestration crisis in adult sickle cell-beta thalassaemia. Postgrad Med J. 1991; 67(792):907 - 908.
    188. Van RF, Blecher TE, DeLepeleire KA, Galloway NR. Bilateral retinal artery occlusion due to mitral valve prolapse. Br J Ophthalmol. 1991; 75(7):436 - 437.
    189. Van RF, Abela M. Coombs negative haemolytic anaemia responding to intravenous immunoglobulins in a patient with myelodysplastic syndrome. Clin Lab Haematol. 1991; 13(1):99 - 101.
    190. Van RF, Beaumont DM. Gastric stricture complicating oral ingestion of bleach. Br J Clin Pract. 1990; 44(12):681 - 682.
    191. Van rhee F, Goldman JM. Cell Therapy. Donor Lymphocyte Therapy in Bone Marrow Transplantation.
    192. Grazziutti, ML, Szmania, S, Kurup, VP, Anaissie, E, Van Rhee, F. Recombinant Aspergullus fumigatus antigen 4 (Af4) induces potent type 1 cellular immune responses: implications for immunotherapy of Aspergillus infections. International Society for Cellular Therapy Annual Meeting.
    Van Rhee's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _